Combination

Sio Silica Corporation to Go Public via Business Combination With Pyrophyte Acquisition Corp., Accelerating Mission to Disrupt the Market for High-Purity Quartz Silica, a Critical Mineral in the World’s Transition to Net Zero

Retrieved on: 
Monday, November 13, 2023
Professional Services, Natural Resources, Mining, Minerals, Finance, Slate, Carbon, Economics, Acquisition, NYSE, Engineering, Business analyst, UBS, PIPE, Combination, Winnipeg Manitoba Temple, LLP, DLA Piper, Investment, Electronics, Piper, White & Case, Nature, Marketing, Natural gas, Semiconductor, Hand, Phase, Growth, Electricity, Business, Transport, ESG, Security (finance), Lithium, Renewable energy, Iron ore, Management, Sio, Stantec, Pyrophyte

Once the processing facility becomes operational, Sio expects to become a leading environmentally friendly producer of high-purity quartz silica, a unique natural resource and critical mineral.

Key Points: 
  • Once the processing facility becomes operational, Sio expects to become a leading environmentally friendly producer of high-purity quartz silica, a unique natural resource and critical mineral.
  • Anticipated applications for Sio’s high-purity quartz silica include photovoltaics, solar panels, semiconductors, electronics and batteries.
  • Expects to become a leader in the rapidly expanding high-purity quartz silica industry with no current plans to rely on government subsidies.
  • High-purity quartz silica currently represents a $30 billion total addressable market by 2030 for photovoltaics, solar panels, semiconductors and batteries.

Vaso Corporation, a Diversified Medical Technology Company Currently Trading on the OTCQX Market, to List on Nasdaq via SPAC Merger

Retrieved on: 
Thursday, December 7, 2023
Sale, Transaction, Radiological information system, Combination, Registration statement, LLP, System, OTCQX, Form, Ladenburg Thalmann, File, Software, Security (finance), Achari, Vaso

The transaction values Vaso at a pro forma equity value of approximately $176 million at $10 per share.

Key Points: 
  • The transaction values Vaso at a pro forma equity value of approximately $176 million at $10 per share.
  • Upon closing of the transaction, existing Vaso shareholders will receive consideration consisting entirely of shares of the surviving public combined company.
  • PLAINVIEW, NY, Dec. 7, 2023 /PRNewswire/ - Vaso Corporation ("Vaso," or "the Company"), a diversified medical technology company currently trading on the OTCQX market, today announced its plan to uplist from the OTCQX market to the Nasdaq Stock Market via a business combination (the "Transaction") with Achari Ventures Holdings Corp.
  • Katten Muchin Rosenman LLP is acting as legal advisor to Achari and Ortoli Rosenstadt LLP is acting as legal advisor to Vaso.

White Glove and TouchFuse Announce Merger, Creating a Full-Service, Omni-Channel Marketing Services Company for Financial Advisors

Retrieved on: 
Wednesday, November 29, 2023
Digital media, Combination, Bradlees, Marketing, The White Gloves, Partnership, Communication, Sales, Financial services, Construction

TROY, Mich. and TAMPA, Fla., Nov. 29, 2023 /PRNewswire/ -- White Glove and TouchFuse, which includes the LeadJig, Prospectix and Acquire Direct businesses, announced today the merger of the two companies, creating  a full-service, omni-channel marketing services company focused exclusively on financial advisors. Financial terms of the transaction were not disclosed. White Glove is backed by Rockbridge Growth Equity ("Rockbridge"), a partnership-oriented middle market private equity firm with a differentiated approach to building and growing companies.

Key Points: 
  • White Glove is backed by Rockbridge Growth Equity ("Rockbridge"), a partnership-oriented middle market private equity firm with a differentiated approach to building and growing companies.
  • "We believe the combination of White Glove and TouchFuse is transformational for the industry, offering financial advisors a one-stop-shop with true omni-channel capabilities and the best of both traditional direct mail and digital media offerings," said Mr. Bogich.
  • "Bringing these two companies together means that advisors will gain access to more marketing solutions all within a single platform," said Mr.
  • "With this merger, White Glove and TouchFuse will become the go-to source for financial advisors, offering critical solutions across the marketing funnel.

Arcfield Acquires Orion Space Solutions

Retrieved on: 
Wednesday, November 29, 2023
CubeSat, Acquisition, Research, Combination, Workforce, Space research, Data analysis, Science, Intelligence, IC, Latham & Watkins, Covington & Burling, Intelligence community, DOD, Government, Management, Satellite, Orion

CHANTILLY, Va., Nov. 29, 2023 /PRNewswire/ -- Arcfield, a leading government technology and mission support provider, announced today that it has completed its acquisition of Orion Space Solutions (Orion), a Colorado-based developer of end-to-end space mission capabilities and solutions.

Key Points: 
  • Combination will deliver space superiority and resiliency solutions to U.S. government agencies
    CHANTILLY, Va., Nov. 29, 2023 /PRNewswire/ -- Arcfield, a leading government technology and mission support provider, announced today that it has completed its acquisition of Orion Space Solutions (Orion), a Colorado-based developer of end-to-end space mission capabilities and solutions.
  • Arcfield and Orion Space Solutions combo will deliver space superiority and resiliency solutions to the  U.S. government
    The acquisition of Orion enhances Arcfield's space exploration and hypersonic detection and tracking capabilities for agencies in the Department of Defense (DOD) and Intelligence Community (IC) by bringing expertise in sensor and payload design, SmallSat and CubeSat spacecraft integration and manufacturing, and space mission operations and data analysis to the company.
  • "Arcfield has a long history of delivering innovative solutions across the space domain, and we believe the acquisition of Orion enhances Arcfield's ability to provide next-generation space technologies in support of DOD and IC missions," said Kevin Kelly, chairman and chief executive officer, Arcfield.
  • "We look forward to welcoming the Orion team into the Arcfield family and further developing our collective solutions."

ProPharma Launches an Integrated MedTech Organization Providing End-to-End Solutions for Innovators

Retrieved on: 
Thursday, November 16, 2023
Odyssey, Real-World Evidence, Data management, Safety, Digital therapeutics, Software, 2005 in television, MDR, Notified body, Companion, Medtech, LDT, U.S. FDA, Verification and validation, FDA, QMS, Medical device, Form FDA 483, Digital, Integrated Global System Model, Wearable computer, Geography, Development, RCO, Combination, SRL Diagnostics, Surveillance capitalism, Quality management, IVDR, Single-frequency network, RWE, Health technology, Pharmaceutical industry, Device

RALEIGH, N.C., Nov. 16, 2023 /PRNewswire-PRWeb/ -- ProPharma Group, the world's largest Research Consulting Organization (RCO) and the leading global provider of regulatory, clinical and quality compliance services for the life sciences industry, has today launched a new Integrated Global MedTech Practice to provide end-to-end solutions for medical technology companies.

Key Points: 
  • ProPharma Group has today launched a new Integrated Global MedTech Practice to provide end-to-end solutions for medical technology companies.
  • "ProPharma's new MedTech practice has extensive experience and offers scalable solutions tailored to client needs, regardless of size or geography" –Dr.
  • The MedTech organization includes Regulatory Strategy, Clinical Strategy and Development, Quality Management and Compliance, Market Access and Reimbursement, and Post Market Surveillance.
  • For more information about ProPharma Group's Global MedTech Practice and its suite of services, please visit https://www.propharmagroup.com/ .

MCRA Announces the Hiring of Former FDA Leadership to Advance its Regenerative Medicine Expertise

Retrieved on: 
Wednesday, November 15, 2023
Regenerative medicine, Associate, Regulatory affairs, Device, Quality assurance, OTP, Clinical trial, Plasma, Tissue, CBER, Patient, CDRH, FDA, Biomedical engineering, Advanced manufacturing, Combination, SVP, Knowledge, Health, MCRA, Medical device, Research, Computer security, Iris, Policy

Dr. Yong and Dr. Marklein bring nearly two decades of FDA regulatory experience to MCRA – making them predominant leaders in this rapidly expanding area of medicine.

Key Points: 
  • Dr. Yong and Dr. Marklein bring nearly two decades of FDA regulatory experience to MCRA – making them predominant leaders in this rapidly expanding area of medicine.
  • Dr. Yong states, "I am thrilled to be joining MCRA at such a critical time for Regenerative Medicine.
  • Dr. Marklein states, "By joining MCRA, I can leverage my regulatory expertise in regenerative medicine to support our clients and drive meaningful change.
  • We are excited to welcome Carolyn and Iris to the MCRA team to foster the expansion of MCRA's focus in the regenerative medicine space."

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Tuesday, November 7, 2023
Neoplasm, Survival, CAR, Combination, Glioma, Therapy, ASO, Regeneron Pharmaceuticals, Head, PD-1, The Co Founder, Merck, CNS, Microglia, Kidney, Bladder cancer, TLR9, OTCQB, CD8, Mouse, Environment, City, Immunotherapy, B cell, Disease, Survival rate, Brain, Society, GL261, Patient, Immunosuppression, Therapure BioPharma Inc, Pharmaceutical industry, Pembrolizumab, Cancer, Duet

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma.

Key Points: 
  • DUET-102 is a double-stranded antisense oligonucleotide (“ASO”) STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma.
  • Glioma is a common type of tumor originating in the glial cells of the brain.
  • DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma.
  • There is an acute need for new treatment options for glioma, which have seen no significant advances in the past decade.

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to December 3, 2023

Retrieved on: 
Friday, November 3, 2023
Combination, VSAC, Acquisition, Exercise, Extension, Bank, Security (finance)

MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced that on November 2, 2023, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from November 3, 2023, to December 3, 2023 (the “Extension”).

Key Points: 
  • MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced that on November 2, 2023, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from November 3, 2023, to December 3, 2023 (the “Extension”).
  • The Company has issued to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This is the first of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The combined company’s common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol “NSIM”.

Altitude Acquisition Corp. Announces Extension of Deadline to Complete Initial Business Combination

Retrieved on: 
Friday, November 3, 2023
Combination, Sponsor, United States Army Acquisition Corps, ALTU, Charter, Altitude, Communications satellite

ATLANTA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (Nasdaq: ALTUU, ALTU, ALTUW) (“Altitude”), announced today that its board of directors (the “Board”), upon request by Altitude’s sponsor, Altitude Acquisition Holdco LLC (the “Sponsor”), has extended the date by which Altitude must consummate an initial business combination (the “Deadline Date”) for an additional month, from November 11, 2023 to December 11, 2023.

Key Points: 
  • ATLANTA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Altitude Acquisition Corp. (Nasdaq: ALTUU, ALTU, ALTUW) (“Altitude”), announced today that its board of directors (the “Board”), upon request by Altitude’s sponsor, Altitude Acquisition Holdco LLC (the “Sponsor”), has extended the date by which Altitude must consummate an initial business combination (the “Deadline Date”) for an additional month, from November 11, 2023 to December 11, 2023.
  • On November 3, 2023, pursuant to the Charter and upon request from the Sponsor, the Board determined to implement an eighth Extension.
  • As previously announced, on April 23, 2023, Altitude entered into a business combination agreement (the “Business Combination Agreement”) with Picard Medical, Inc. (“Picard”) and the other parties thereto, which provides for a business combination between Altitude and Picard.
  • The purpose of this monthly Extension is to provide Altitude with additional time to consummate the proposed business combination with Picard.

Notice of Extraordinary General Meeting of Shareholders

Retrieved on: 
Tuesday, October 31, 2023
Menachem Begin, FOR, Section 320 of the Indian Penal Code, Proxy, Court, Private law, Crimes (Substituted Section 59) Amendment Act 2007, Risk, Proxy statement, Anguillan company law, Combination, Business analyst, Form, NIS, CHEK, Internet, Judgement, Motion, Person, Notice, Growth, Haifa District, AND, Letter, Meeting, Mass meeting, Attention, Malczewski, Post office box, Prospectus, YOU, Holding company, Security (finance), Isfiya, Keystone

Only shareholders of record at the close of business on November 6, 2023, are entitled to notice of and to vote at the Meeting or at any adjournment thereof.

Key Points: 
  • Only shareholders of record at the close of business on November 6, 2023, are entitled to notice of and to vote at the Meeting or at any adjournment thereof.
  • On October 30, 2023, Symetryx publicly filed a notice attempting to convene an extraordinary general meeting of shareholders of the Company for Monday, December 4, 2023, at 4:00pm, Israel time, for the replacement of Check-Cap’s Board, pursuant to Section 64 of the Companies Law.
  • We believe that under such circumstances, it is evident that the Company (and its shareholders) will not be harmed by including both matters on the agenda of a single extraordinary general meeting of shareholders; therefore, there is no need or justification for compelling the Check-Cap Board to convene an additional, separate extraordinary general meeting of shareholders specifically for director elections, within a matter of a few days or weeks prior to the date of the extraordinary general meeting that will be convened for the approval of the Keystone transaction, with all the associated costs.
  • At least two shareholders present, in person or by proxy, will constitute a quorum at the adjourned meeting.